statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec Immunic, Inc. Strengthens Its Board of Directors with the Appointment of...

Immunic Stock (NASDAQ:IMUX): Exploring the Promising Phase 2 CALLIPER Trial

Immunic, Inc. ($IMUX) is a clinical-stage biotechnology company, headquartered in New York City. However, most of the company's research and develo...

Immunic Appoints Jason Tardio as Chief Operating Officer and President

Immunic Appoints Jason Tardio as Chief Operating Officer and President Immunic Appoints Jason Tardio as Chief Operating Officer and President PR Newswire NEW YORK, July 9, 2024 Former Novartis and...

Immunic Stock (IMUX): Understanding the Current Status and Future Path for IMU-838

Clinical-stage biotechnology company Immunic, Inc. (NASDAQ:IMUX) is focused on developing an orally administered, small-molecule therapy for treati...

Immunic to Participate in Industry and Scientific Conferences in June

Immunic to Participate in Industry and Scientific Conferences in June Immunic to Participate in Industry and Scientific Conferences in June PR Newswire NEW YORK, May 28, 2024 NEW YORK, May 28, 2024...

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire NEW YORK...

Immunic to Participate in Investor and Scientific Conferences in May

Immunic to Participate in Investor and Scientific Conferences in May Immunic to Participate in Investor and Scientific Conferences in May PR Newswire NEW YORK, May 6, 2024 NEW YORK, May 6, 2024...

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31...

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology & Neuroinflammation

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology...

Immunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital Management

Investment analysts at Brookline Capital Management began coverage on shares of Immunic (NASDAQ:IMUX - Get Free Report) in a research report issued to clients and investors on Friday, Benzinga...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Volume	200,569.00
52-Wk High	$2.45
52-Wk Low	$0.9451

IMUX Immunic Inc

About

Feed

News

Sentiment

Earnings

Fundamentals